X4 Pharmaceuticals Q2 2024 GAAP EPS $0.45 Beats $0.01 Estimate, Sales $563.000K Beat $278.667K Estimate
Portfolio Pulse from Benzinga Newsdesk
X4 Pharmaceuticals (NASDAQ:XFOR) reported Q2 2024 GAAP EPS of $0.45, significantly beating the analyst estimate of $0.01. The company also reported quarterly sales of $563,000, surpassing the estimate of $278,667 by 102.03%.
August 08, 2024 | 10:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
X4 Pharmaceuticals reported Q2 2024 GAAP EPS of $0.45, beating the analyst estimate of $0.01 by 4400%. Quarterly sales of $563,000 also exceeded the estimate of $278,667 by 102.03%.
The significant beat in both EPS and sales indicates strong financial performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100